Long-term statin use in patients with lung cancer and dyslipidemia reduces the risk of death

Oncotarget. 2016 Jul 5;7(27):42208-42215. doi: 10.18632/oncotarget.9906.

Abstract

Background: Clinical studies have obtained inconsistent results of statin use on cancer outcomes. This study investigated the association between statin use and lung cancer mortality.

Results: The use of statin decreased mortality (hazard ratio = 0.91; 95% confidence interval: 0.86-0.96; P < .01). The patients with a high cumulative defined daily dose of statin use before lung cancer diagnosis exhibited a low risk of mortality.

Materials and methods: We conducted a population-based case-control study of patients with dyslipidemia. Among them, 6270 had used statins for at least 3 months before lung cancer diagnosis, and 6270 had never used statins.

Conclusions: We found that statin use can reduce lung cancer mortality. A further prospective study is necessary to confirm these findings.

Keywords: lung cancer; population-based case-control study; statin.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Case-Control Studies
  • Dyslipidemias / complications
  • Dyslipidemias / drug therapy*
  • Dyslipidemias / mortality
  • Female
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
  • Incidence
  • Lung Neoplasms / complications
  • Lung Neoplasms / mortality*
  • Male
  • Middle Aged
  • Proportional Hazards Models
  • Prospective Studies
  • Risk Factors
  • Taiwan
  • Time Factors
  • Treatment Outcome
  • Young Adult

Substances

  • Hydroxymethylglutaryl-CoA Reductase Inhibitors